Abstract
Design:
Study part 1 was executed as a randomized double-blind placebo-controlled crossover study and study part 2 as a longitudinal study.
Subjects:
Forty-one healthy adult volunteers aged 18–24 years were recruited from the student population of the University of Salford. All subjects enrolled and completed study part 1 and 39 subjects enrolled and completed study part 2.
Interventions:
In study part 1, individuals consumed, in random order 0, 20, 40, 60, 80, 100 or 120 g of a RRM containing starch product incorporated in pre-prepared foods on individual test days. Assuming a minimum content of 50% RRM in the starch product this delivered respectively 0, 10, 20, 30, 40, 50 or 60 g of RRM. All foods were prepared and coded by personnel not involved in carrying out the tests. Test days were separated by 7 day washout periods. In study part 2, consumption of RRM was increased from 3.6 g at day 1 in incremental doses up to each subject's MNED as determined in study 1, to be achieved at day 14. Subsequently, RRM intake was from day 15–21 in a way that the final intake at day 21 was at least 10 g above the individual MNED. In both parts of the study, subjects reported the prevalence and magnitude of GI symptoms.
Results:
No significant change was observed in either defecation frequency and faecal consistency or the number of subjects experiencing any GI symptoms, following consumption of foods containing 0–60 g RRM. The individual MNED at which an increase in symptoms did not occur was determined as 60 g RRM for 71% of the subjects who participated in study part 1. Regression analysis showed that consumption of gradually increasing doses of RRM in food products over 21 days was associated with a significant increase in the mean symptom score for flatulence (P=1.5 × 10−4), total bowel movement frequency (P=0.023) and bowel movement frequency to pass watery faeces (P=0.0157). Increasing the ingested dose of RRM by 10 g above the predetermined MNED, however, did not provoke significant increases in GI symptoms. In both studies, the majority of symptom responses were classified by the subjects as ‘little more than usual’.
Conclusions:
Consumption of up to 60 g RRM is tolerated well by most individuals with no evidence of any significant dose-dependent increase in the magnitude of symptoms or the occurrence of multiple GI symptoms. However, a mild laxative effect when consuming >60 g RRM is suggested. Although there was no change in GI responses following consumption of increasing doses of RRM over 21 days, generally a dose of 10 g RRM above the MNED level was tolerated well during medium term intake.
Sponsorship:
Cerestar-Cargill R&D Center, Vilvoorde, Belgium.
The gastrointestinal (GI) responses to ingested digestion resistant retrograded maltodextrins, having a structural similarity to type 3 resistant starch (RS) but a lower molecular weight, were studied after acute single bolus ingestion as well as during a medium-term period of daily ingestion. The overall study was split into two parts: part 1 aimed (1) to determine the GI responses of young adults following consumption of 0–60 g resistant maltodextrin; (2) to define the maximum non-effective dose (MNED) at which a considerable increase in symptoms did not occur. Part 2 aimed to determine whether a gradual increase in the daily dose of retrograded resistant maltodextrin (RRM) to a level finally exceeding by at least 10 g the individually determined MNED to acute ingestion in part 1 of the study, modified tolerance over time.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Achour L, Flourié B, Briet F, Franchisseur C, Bornet F, Champ M, Rambaud JC et al. (1997). Metabolic effects of digestible and partially indigestible cornstarch: a study in the absorptive and postabsorptive periods in healthy humans. Am J Clin Nutr 66, 1151–1159.
Asp NG (1997). Resistant starch – An update on its physiological effects. Adv Exp Med Biol 427, 201–210.
Asp NG (1992). Resistant starch – Proceedings from the second plenary meeting of EURESTA: European FLAIR Concerted Action No.11 on physiological implications of the consumption of resistant starch in man. Preface Eur J Clin Nutr 46, S1.
Asp NG, van Amelsvoort JMM, Hautvast JGAJ (1996). Nutritional implications of resistant starch. Nutr Res Rev 9, 1–31.
Baghurst PA, Baghurst KI, Record SJ (1996). Dietary fibre, non-starch polysaccharides and resistant starch – a review. Food Aust 48, S1–S36.
Bird AR, Brown IL, Topping DL (2000). Starches, resistant starches, the gut microflora and human health. Curr Issues Intest Microbiol 1, 25–37.
Birkett AM, Jones GP, deSilva AM, Young GP, Muir JG (1997). Dietary intake and faecal excretion of carbohydrate by Australians: importance of achieving stool weights greater than 150 g to improve faecal markers relevant to colon cancer risk European. J Clin Nutr 51, 625–632.
Briet F, Achour L, Flourié B, Beaugerie L, Pellier P, Franchisseur C et al. (1995). Symptomatic response to varying levels of fructo-oligosaccharides consumed occasionally or regularly. Eur J Clin Nutr 49, 501–507.
Brighenti F, Casiraghi MC, Baggio C (1998). Resistant starch in the Italian diet. Br J Nutr 80, 333–341.
Brouns F, Kettlitz B, Arrigoni E (2002). Resistant starch and ‘the butyrate revolution. Trends Food Sci Technol 13, 251–261.
Brousseau AD, Dufour A, Volatier JL (1998). Assessment of resistant starch consumption in France and the nutritional impact of its use in an increasing number of foodstuffs. Internal Report of CREDOC – Département Prospective de la Consommation, Paris, France.
Champ M, Langkilde AM, Brouns F, Kettlitz B, Le Bail-Collet Y (2003). Advances in dietary fibre characterization. 2. Consumption, chemistry, physiology and measurement of resistant starch; implications for health and food labeling. Nutr Res Rev 16, 143–161.
Cummings JH, Beatty ER, Kingman SM, Bingham SA, Englyst HN (1996). Digestion and physiological properties of resistant starch in the human large bowel. Br J Nutr 75, 733–747.
Cummings JH, Bingham S, Heaton KW, Eastwood MA (1992). Faecal weight, colon cancer risk and dietary intake of non-starch polysaccharides (dietary fibre). Gastroenterology 103, 1783–1789.
Cummings JH, Englyst HN (1991). Measurement of starch fermentation in the human large intestine. Can J Physiol Pharmacol 69, 121–129.
Edwards JHC, Gee J, Nagengast F, Mathers J (1995). Physiological effects of resistant starch in the large bowel. In: (Asp NG, van Amelsvoort JMM, Hautvast JGAJ (eds) Proceedings of the Concluding Plenary Meeting of EURESTA. European Flair-Concerted Action on Resistant Starch – No. 11. (COST 911) pp. 38–55.
Englyst HN, Cummings JH (1986). Digestion of the carbohydrates of banana (Musa paradisiaca sapientum) in the human small intestine. Am J Clin Nutr 44, 42–50.
Englyst HN, Cummings JH (1987). Digestion of the polysaccharides of potato in the small intestine of man. Am J Clin Nutr 45, 423–431.
Englyst HN, Kingman SM, Cummings JH (1992). Classification and measurement of nutritionally starch fractions. Eur J Clin Nutr 46, S33–S50.
Englyst HN, Kingman SM, Hudson GJ, Cummings JH (1996). Measurement of resistant starch in vitro and in vivo. Br J Nutr 75, 749–755.
European Patent Office. Patent nr Bulletin 2002/11.EP 0 846 704.
Faisant N, Buléon A, Colonna P, Molis C, Lartigue S, Galmiche JP et al. (1995a). Digestion of raw banana starch in the small intestine of healthy humans : structural features of resistant starch. Br J Nutr 73, 111–123.
Faisant N, Champ M, Ranganathan SS, Azoulay C, Kergueris MF, Krempf M (1994). Effects of resistant starch supplementation on postprandial metabolism in healthy subjects. In: Asp NG, van Amelsvoort JMM, Hautvast JGAJ (eds) Proceedings of the Concluding Plenary Meeting of EURESTA p. 113–114.
Faisant N, Planchot V, Kozlowski F, Pacouret MP, Colonna P, Champ M (1995b). Resistant starch determination adapted to products containing high level of resistant starch. Sciences des Aliments 15, 83–89.
Flourié B, Briet F, Florent C, Pellier P, Maurel M, Rambaud JC (1993). Can diarrhea induced by lactulose be reduced by prolonged ingestion of lactulose? Am J Clin Nutr 58, 369–375.
Haralampu SG (2000). Resistant starch – a review of the physical properties and biological impact of RS3. Carbohyd Polym 41, 285–292.
Hata Y, Yamamoto M, Nakajima K (1991). Effects of soybean oligosaccharides on human digestive organs: estimation of fifty percent effective dose and maximum non-effective dose based on diarrhea. J Clin Biochem Nutr 10, 135–144.
Heijnen ML, Deurenberg P, van Amelsvoort JM, Beynen AC (1997). Retrograded (RS3) but not uncooked (RS2) resistant starch lowers fecal ammonia concentrations in healthy men. Am J Clin Nutr 65, 167–169.
Heijnen MLA, van Amelsvoort JMM, Deurenberg P, Beynen AC (1996). Neither raw nor retrograded resistant starch lowers fasting serum cholesterol concentrations in healthy normolipidemic subjects. Am J Clin Nutr 64, 312–318.
Hertzler SR, Savaiano DA (1996). Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance. Am J Clin Nutr 64, 232–236.
Hylla S, Gostner A, Dusel G, Anger H, Bartram H-P, Christl SV et al. (1998). Effects of resistant starch on the colon in healthy volunteers: possible implications for cancer prevention. Am J Clin Nutr 67, 136–142.
Johnson AO, Semenya JG, Buchowski MS, Enwonwu CO, Scrimshaw NS (1993). Adaptation of lactose maldigesters to continued milk intakes. Am J Clin Nutr 58, 879–881.
Kingman SM, Englyst HN (1994). The influence of food preparation methods on the in-vitro digestibility of starch in potatoes. Food Chem 49, 181–186.
Kleessen B, Stoof G, Proll J, Schmiedl D, Noack J, Blaut M (1997). Feeding resistant starch affects fecal and cecal microflora and short-chain fatty acids in rats. J Anim Sci 75, 2453–2462.
Koutsou GA, Storey DM, Lee A, Zumbé A, Flourié B, Le bot Y et al. (1996). Dose-related gastrointestinal response to the ingestion of either isomalt, lactitol or maltitol in milk chocolate. Eur J Clin Nutr 50, 17–21.
Langkilde AM, Phillipsson H, Andersson H, Brouns F (2002). Internal Report from an In Vivo Measurement of RS. University of Gotenburg: Sweden.
LeBlay G, Michel C, Blottiere HM, Cherbut C (1999). Enhancement of butyrate production in the rat caecocolonic tract by long-term ingestion of resistant potato starch. Br J Nutr 82, 419–426.
Lee A, Storey DM (1999). Comparative gastrointestinal tolerance of sucrose, lactitol or D-tagatose in chocolate. Regul Toxicol Pharmacol 29, S78–S82.
MacFarlane GT, Hay S, Gibson GR (1988). Influence of mucin on glycosidase, protease and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture system. J Appl Bacteriol 66, 407–417.
McNemar Q (1947). Note on the sampling error of the difference between correlated proportions or percentages. Psychometrica 12, 153–157.
Noah L, Guillon F, Bouchet B, Buléon A, Molis C, Gratas M et al. (1998). Digestion of carbohydrate from home cooked white beans (Phaseolus vulgaris L) in healthy humans. J Nutr 128, 977–985.
Olesen M, Rumessen JJ, Gudmandhoyer E (1994). Intestinal transport and fermentation of resistant starch evaluated by the hydrogen breath test. Eur J Clin Nutr 48, 692–701.
Phillips J, Muir JG, Birkett A, Lu ZX, Jones GP, O’dea K et al. (1995). Effect of resistant starch on fecal bulk and fermentation – dependent events in humans. Am J Clin Nutr 62, 121–130.
Rambaud JC, Flourié B (1994). Mechanism of carbohydrate-induced diarrhea. In Binder HJ, Cummings JH, Soergel K (eds) Short chain fatty acids. Kluwer Academic Publishers: Dodrecht, pp 232–239.
Ranganathan S, Champ M, Pechard C, Blanchard P, N’Guyen M, Colonna P et al. (1994). Comparative study of the acute effects of resistant starch and dietary fibers on metabolic indexes in man. Am J Clin Nutr 59, 879–883.
Siegel S (1988). Nonparametric statistics for the behavioral sciences. McGraw-Hill: New York.
Silvi S, Rumney CJ, Cresci A, Rowland IR (1999). Resistant starch modifies gut microflora and microbial metabolism in human flora-associated rats inoculated with faeces from Italian and UK donors. J Appl Microbiol 86, 521–530.
Tomlin J, Read NW (1990). The effect of resistant starch on colon function in humans. Br J Nutr 64, 589–595.
Topping DL, Bird AR (1999). Foods, nutrients and digestive health. Aust J Nutr Diet 56, S22–S34.
Topping DL, Clifton PM (2001). Short-Chain Fatty Acids and Human Colonic Function. Roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81, 1031–1064.
Van munster IP, Nagengast FM (1993). The role of carbohydrate fermentation in colon-cancer prevention. Scand J Gastroenterol 200, 80–86.
Van Munster IP, Tangerman A, Nagengast FM (1994). Effect of resistant starch on colonic fermentation, bile acid metabolism and mucosal proliferation. Digest Dis Sci 39, 834–842.
Wisker E (2000). Physiological effects of resistant starch - Part 1: Definition, intake with food, and influence on glucose, insulin and lipid plasma levels. Ernahrungs-umschau 47, 10–15.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Storey, D., Lee, A., Bornet, F. et al. Gastrointestinal responses following acute and medium term intake of retrograded resistant maltodextrins, classified as type 3 resistant starch. Eur J Clin Nutr 61, 1262–1270 (2007). https://doi.org/10.1038/sj.ejcn.1602642
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejcn.1602642